» Articles » PMID: 32030252

Clinical Outcomes of Transcatheter Versus Surgical Pulmonary Valve Replacement: a Meta-analysis

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2020 Feb 8
PMID 32030252
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Transcatheter pulmonary valve replacement (TPVR) has currently been a well-established alternative operation method to surgical pulmonary valve replacement (SPVR) in patients with pulmonary valve dysfunction in the form of stenosis and/or regurgitation. We conducted a meta-analysis to evaluate the main clinical outcomes after TPVR and SPVR.

Methods: We systematically searched the references of relevant literatures from PubMed and the Cochrane Library published between January 2000 and December 2018 and followed The Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) for this study.

Results: Eleven studies with 4,364 patients were included in the study. Compared with SPVR, TPVR results in a significant decreased in-hospital mortality [odds ratio (OR): 0.18; 95% confidence interval (CI): 0.03-0.98] and mortality at the longest reported follow-up time point (OR: 0.43; 95% CI: 0.22-0.87), though 30-day mortality (OR: 0.38; 95% CI: 0.11-1.33) has no significant difference between groups. Days of hospital stay [(mean difference (MD): -4.38; 95% CI: -6.24--2.53] is shorter with TPVR than SPVR. Besides, rates of 30-day readmission (OR: 0.67; 95% CI: 0.50-0.91) and recurrent pulmonary regurgitation (OR: 0.17; 95% CI: 0.07-0.42) are lower with TPVR, whereas postprocedural infective endocarditis (IE) (OR: 4.56; 95% CI: 2.03-10.26) are higher with TPVR. SPVR carries a decreased risk of re-operation (OR: 2.19; 95% CI: 0.62-7.76) though without statistically significance.

Conclusions: In conclusion, TPVR is associated with a significantly decreased mortality, a shorter length of hospital-stay, a lower rate of 30-day readmission and recurrent pulmonary regurgitation as compared to SPVR throughout the follow-up duration, whereas SPVR results in a significantly lower rate of postprocedural IE than TPVR. In addition, SPVR carries a decreased risk of re-operation with statistically insignificance.

Citing Articles

Multimodality Imaging Evaluation of Diseases of the Pulmonic Valve and Right Ventricular Outflow Tract for the Adult Cardiologist.

Murphy S, Sultana S, Zern E, Tower-Rader A, Churchill J, Stefanescu Schmidt A Circ Cardiovasc Imaging. 2025; 18(2):e017126.

PMID: 39801475 PMC: 11835535. DOI: 10.1161/CIRCIMAGING.124.017126.


Minimally invasive pulmonary valve replacement through a left anterior minithoracotomy in young patients with pectus excavatum. The procedure of choice.

Ioannou S, Shiakos G, Ocker V, Rousounides A, Tzanavaros I J Surg Case Rep. 2024; 2024(8):rjae500.

PMID: 39119537 PMC: 11308932. DOI: 10.1093/jscr/rjae500.


Occurrence and Outcome of Infective Endocarditis after Surgical Compared to Transcatheter Pulmonary Valve Implantation in Congenital Heart Disease.

Fischer A, Enders D, Baumgartner H, Diller G, Kaleschke G J Clin Med. 2024; 13(9).

PMID: 38731212 PMC: 11084703. DOI: 10.3390/jcm13092683.


Catheter-based Interventions in Tetralogy of Fallot Across the Lifespan.

Wong N, Shorofsky M, Lim D CJC Pediatr Congenit Heart Dis. 2024; 2(6Part A):339-351.

PMID: 38161670 PMC: 10755836. DOI: 10.1016/j.cjcpc.2023.09.005.


Risk of Infective Endocarditis Post-transcatheter Pulmonary Valve Replacement Versus Surgical Pulmonary Valve Replacement: A Systematic Review.

Slouha E, Johnson L, Thirunavukarasu A, Al-Geizi H, Clunes L, Kollias T Cureus. 2023; 15(10):e48022.

PMID: 38034152 PMC: 10687661. DOI: 10.7759/cureus.48022.


References
1.
DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

2.
Hascoet S, Acar P, Boudjemline Y . Transcatheter pulmonary valvulation: current indications and available devices. Arch Cardiovasc Dis. 2014; 107(11):625-34. DOI: 10.1016/j.acvd.2014.07.048. View

3.
Bearl D, Fleming G . Utilizing Hybrid Techniques to Maximize Clinical Outcomes in Congenital Heart Disease. Curr Cardiol Rep. 2017; 19(8):72. DOI: 10.1007/s11886-017-0878-2. View

4.
Agrawal H, AlKashkari W, Kenny D . Evolution of hybrid interventions for congenital heart disease. Expert Rev Cardiovasc Ther. 2017; 15(4):257-266. DOI: 10.1080/14779072.2017.1307733. View

5.
OByrne M, Gillespie M, Shinohara R, Dori Y, Rome J, Glatz A . Cost comparison of Transcatheter and Operative Pulmonary Valve Replacement (from the Pediatric Health Information Systems Database). Am J Cardiol. 2015; 117(1):121-6. PMC: 4690775. DOI: 10.1016/j.amjcard.2015.10.011. View